Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 8/20 | 0.38 |
| ▸ | CYP21A2 | P08686 | 8/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3000938 | 1.00 | MAOB (0.38) | MAOBCYP17A1CYP21A2CYP11B1CYP3A4 | |
| SCHEMBL1136795 | 0.89 | ABCB1 (0.46) | MAPTALK | |
| SCHEMBL1136797 | 0.89 | ABCB1 (0.46) | MAPTALK | |
| SCHEMBL1136842 | 0.82 | ALPL (0.32) | MAOBCYP17A1CYP21A2CYP11B1P4HB | |
| SCHEMBL1136850 | 0.82 | ALPL (0.32) | MAOBCYP17A1CYP21A2CYP11B1P4HB | |
| SCHEMBL1136702 | 0.81 | CYP17A1 (0.41) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL1136704 | 0.81 | CYP17A1 (0.41) | CYP17A1CYP21A2CYP11B1CYP3A4CYP19A1 | |
| SCHEMBL578443 | 0.74 | LIPG (0.44) | P4HB | |
| SCHEMBL1136706 | 0.73 | MAPT (0.44) | MAOBMAPTACHEALK | |
| SCHEMBL1136707 | 0.73 | MAPT (0.44) | MAOBMAPTACHEALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786120-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20070185125-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185125-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | MAOB 912/4885CYP17A1 3080/4885CYP21A2 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.